The rate of death or HF hospitalization was not influenced by the presence of leads after accounting for comorbidity burden.

Researchers hoped the technique might involve lower exposure compared with right transradial access, but this didn’t pan out.

This month: clinicians’ views on CVD prevention, a possible sleep apnea paradox, microplastics in femoral plaque, and more.

Juan Granada, Roxana Mehran, and Tricia Rawh provide a preview of what's to come at TCT 2025.

More work needs to be done to tease out the mechanisms by which GLP-1 RAs lower the risk of MACE, researchers say.

Even among light-to-moderate drinkers, cutting back on booze can have a positive effect on blood pressure, researchers showed ...

Given that polygenic risk doesn’t change and only needs to be measured once, researchers advocate greater use.

More focus is needed on female-specific barriers to enrollment and completion of programs that can improve their outcomes.

In the recent SOUL trial, the GLP-1 drug reduced the risk of MACE by 14% over 4 years. Next up: a possible obesity indication ...

Experts continue to debate whether the health status benefits are real and enough to justify doing the procedures for severe ...

The “uneven playing field” related to demographics could be smoothed by stroke networks and standardized care.